Comments
Johnson and Johnson on Tuesday, 20 April, said that it will resume roll-out of its single-shot COVID-19 vaccine in Europe after the European Union’s drug regulator announced that blood clots were a very rare side effect of the vaccine and “its benefits outweigh the risk”.
The European Medicines Agency (EMA) has recommended a warning should be added to the vaccine’s product information.
“Healthcare professionals and people who receive the vaccine should be aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within three weeks of vaccination,” stated the EMA.